← All trials
NCT06366698
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 21, 2023
- Primary completion
- Dec 30, 2025
- Completion date
- Dec 30, 2025
- First posted
- Apr 16, 2024
- Last posted
- Apr 16, 2024
- Enrollment
- 900
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of California, IrvineLead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.